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Tinamarie Hanson
Balancing Individualized Needs of Terminal Patients with Broader Societal Interests
Introduction
In September 2011, Nick Auden was faced with news that no one – especially a middle
aged man with a wife and young children – wants to hear: he was diagnosed with melanoma and
given a death sentence within a year.1 Determined to fight his illness, Nick enrolled in a clinical
trial for a promising new, investigational drug designed to treat his form of melanoma.2 The
drug was a ray of hope for Nick, with New York’s Memorial Sloan-Kettering Cancer Center
oncologist Jedd Wolchok even stating that the drug could benefit patients “for months or years.”3
For an individual such as Nick, in the prime of his life and with young children, even a small
amount of added time with his family would be a godsend.
Unfortunately, almost immediately after qualifying for the clinical trial, Nick was
disqualified when he fell ill with a perforated intestine.4 Still determined to obtain the drug, he
applied for a compassionate use exception, meaning he would be able to obtain the drug outside
of the clinical trials process and prior to it being approved to go on the market.5 However, he
was denied his request.6 Even after obtaining 500,000 signatures on change.org, and after
garnering more than 31,000 followers on his facebook page, Nick was unable to motivate the
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drug company, Merck, to budge and allow his compassionate use request.7 Sadly, Nick passed
away in November 2013, leaving behind his wife and three young children – aged 7, 5, and 1.8
This paper will analyze the issues that arise when terminal patients, such as Nick Auden,
who have tried all other forms of treatment, seek to obtain an investigational drug with the hopes
that it may treat or mitigate their condition. While these patients have a strong interest in
obtaining these drugs as quickly as possible - this is usually their last hope for a possible cure
after all conventional forms of treatment have failed - drug companies and their stakeholders
have several reasons for denying early use, such as liability concerns that come along with giving
drugs out prior to approval, as well as the chance that the clinical trials process will be adversely
affected. This paper will analyze the balance between the terminal patient’s interests and the
drug company’s interest, and conclude with a discussion of the best possible outcome for all
involved.
The paper will start out with a discussion of the history of the FDA, which tightly
regulates drug production, and why this regulation is necessary. The paper will then go on to
discuss the typical process of clinical trials and approval of a new drug. Next, the paper will
discuss current ways in which individuals obtain drugs earlier than the typical market approval
rate, chiefly expedited approval and compassionate use. The paper will then go on to discuss the
more controversial way in which individuals obtain drugs prior to approval - through
compassionate use exceptions - and why this is often frowned upon by drug companies. Then,
the paper will discuss some of the pushback created by terminal patients and their supporters in
an attempt to get drugs to patients more quickly: first the judicial avenue that has been taken,
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and then the legislative attempts. Next, this paper will elaborate on 2009 changes in FDA
regulation intended to help improve the current process. Finally, the paper will discuss more
recent changes in 2014 which have helped improve the drug approval process, and how these
changes, mainly expediting of the drug approval process, paired with a proper balancing of
compassionate use allowances, hold the most promise for striking a balance between the needs of
terminal patients and the needs of drug companies to properly test their drugs before allowing
those drugs to be given to the public or to individuals outside of the clinical trial setting.
FDA History
If you were an ill patient prior to the 1900s, there were few government imposed hurdles
that would impede your efforts to obtain a potentially life-saving drug. However, starting in the
1900’s the United States government began to steadily increase its regulatory power over drug
manufacturer’s, which in turn affected consumers’ ability to obtain drugs.
In 1906, the government responded to journalists’ widespread reporting on improper
conditions in both food processing and marketing patent medicine by passing the Pure Food and
Drugs Act of 1906.9 This law put no hurdles in front of a product prior to its marketing, but it
did specify conditions under which foods and drugs would be considered adulterated or
misbranded.10 This was significant in that it required food and drug manufacturers to make sure
that their products were manufactured under sanitary conditions and labeled properly.11 This law
had an only minimal effect on industry and was followed by increasingly strict legislation.
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In 1938, over one hundred individuals died from consuming an antibiotic, Elixir
Sulfanilamide, which contained antifreeze.12 This prompted the passage of the Food, Drug, and
Cosmetic Act of 1938, which delegated authority to the FDA to monitor food and drugs.13
Specifically, in regard to drugs, it authorized the FDA to ensure that drugs placed on the market
were considered safe.14 While a manufacturer was not required to gain explicit FDA approval
prior to marketing its drug, it was required to at the very least to conduct tests to establish
whether or not the drug was safe, and to submit the drug to the FDA for an independent review.15
The drug would automatically be approved for commercial distribution unless the FDA later
determined it not to be safe.16 The law in 1938 was particularly significant since, for the first
time, the government imposed some sort of safety standards upon drug manufacturers.
A public health crisis again led to tighter regulations in 1962. After thousands of
European women who had taken the morning sickness drug Thalidomide gave birth to children
with severe birth defects, Congress passed the Kefauver-Harris Amendments of 1962.17
Although this health crisis had happened in Europe, the FDA realized that greater protections
would be necessary to prevent a similar crisis from possibly occurring at some point in the
United States. These Amendments put a much higher burden on drug manufacturers, requiring
them to submit “substantial evidence” of a drug’s efficacy prior to putting it on the market.18
The substantial evidence standard required a drug company to perform clinical trials and submit
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a great deal of evidence as to a drug’s efficacy to the FDA, prior to being permitted to market the
drug.19 The drug approval process now takes on average seven years.20
In 1997, in an attempt to offset this lengthy process, the FDA passed the FDA
Modernization Act of 1997.21 This Act authorized the Secretary of Health and Human Services
to accelerate the development and approval of a drug that was to be used for terminally ill
patients with no other viable options.22 The Modernization Act basically set the foundation for
expedited review processes in certain situations, in order to get life-saving drugs to market more
quickly.23
Drug Approval Process
As a result of this increasing regulation, there are several steps a drug company must
walk through in order to gain approval as a new drug. Before even beginning clinical trials on
humans, a drug company must submit an Investigational New Drug Application (IND) to the
FDA, including detailed information on the drug as well as information on the proposed clinical
investigation.24 Prior to submitting the IND, a drug company must do animal testing in order to
establish at least some baseline for safety before moving on to human clinical trials.25
Once a drug company is permitted to move on to human clinical trials, it generally has to
go through several phases of testing before gaining new drug approval. Phase I testing is done
on a very small number of healthy subjects, usually 20-80 individuals, primarily to determine
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safety related information such as “the metabolism and pharmacologic actions of the drug in
humans, [and] the side effects associated with increasing doses.”26 Additionally, the researchers
sometimes will gain early evidence of effectiveness.27
In the next stage, phase II studies expand the group of research participants up to several
hundred individuals and include individuals afflicted with the disease being studied.28 Phase II
studies focus more heavily on the drug’s effectiveness as well as optimal dosage ranges, while
still looking at any risks or side effects associated with the drug.29
Finally, Phase III studies are the most detailed, including thousands or participants and
often taking place at multiple locations.30 These studies are focused on obtaining “substantial
evidence” to meet the FDA’s standards for proof of “safety and efficacy” needed to obtain new
drug approval.31
After completing phase III studies, a drug company will submit its new drug application
to the FDA and hope for a timely approval.32 Sometimes, the FDA will ask for more information
and the approval process can still linger on for some time.33 Overall, it takes an average of seven
years for a new drug to be approved.34
For terminally ill individuals, waiting for a potentially life-saving drug to be approved
under this lengthy process is not usually a viable option. While these individuals can attempt to
enroll in clinical trials to obtain the drug, they are sometimes excluded as not meeting the
26
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criteria; if they are accepted, they run the risk of being placed into a placebo group and not
gaining access to the drug at all.35 Thus, over time policies have been implemented that allow
for an expedited review process for particularly promising drugs.36 Additionally, compassionate
use policies have been established which allow certain terminally ill patients a chance to gain
access to drugs that have not yet completed all phases of clinical testing.37
Expedited Approval
The FDA has established ways in which a drug may be approved much more quickly
than the average 7 year timeline. The primary way in which this occurs is through a drug’s
designation to the “Fast Track” program.38 A drug designated for the fast track approval process
must be intended to treat a life threatening or very serious condition.39 The drug must also be
intended to address an unmet medical need; an unmet medical need can be as straightforward as
there being no other therapy available, or it can mean that the drug has “improved efficacy over
existing therapies; efficacy for serious elements of a condition that are not treated by existing
therapies; efficacy in patients who do not respond to or cannot tolerate existing therapy; or
reduction in serious toxicity of existing therapies, or avoiding other toxicities that cause
discontinuation of treatment with other therapies.”40
For a drug that qualifies for fast track designation, the FDA takes on a more active and
collaborative role throughout the drug development process, in order to help expedite the
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development and review of the drug.41 This hands on and more active role can make a
significant difference in getting a drug to market much more quickly than the usual lengthy
timeline. For example, AZT, the first drug approved for treating the AIDS virus, had a total drug
approval time of only two years.42 This is significantly lower than the average seven year
process for drug approval. Undoubtedly, many lives were saved by the expedited approval of
this life saving drug, for many individuals were able to gain access to it years before it would
have hit the market under the usual drug approval process. Thus, expedited review plays a
pivotal role in helping certain drugs become accessible to the general public much more quickly.
Compassionate Use
Shortening approval time by several years may be very helpful to some patients, but for
others who may only have weeks to months to live, this might not be enough. Thus, the FDA
has also established compassionate use policies that allow some individuals to gain access to
drugs which have not yet been approved.43 The FDA’s compassionate use programs cater to
both individuals and intermediate size patient populations who have a “serious or immediately
life-threatening disease or condition…[with] no comparable or satisfactory alternative therapy to
diagnose, monitor, or treat the disease or condition.”44 For a drug to be approved for
compassionate use, the potential benefit to the person or groups being treated must outweigh the
potential risks to the person or group of individuals.45 Additionally, making the drug available
through compassionate use to the person or individuals must not interfere with the clinical trials
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process.46 In rare instances, compassionate use will allow an individual to gain access to a drug
as early as post phase I testing, but generally it will only allow an individual access after the drug
has entered or completed phase II testing.47
For many terminal individuals who cannot get approved to participate in clinical trials,
and for whom all existing treatment is not working, the opportunity to gain access to a drug
through compassionate use is a last hope. Yet, drug companies sometimes deny compassionate
use requests, due to several valid concerns.
Lack of Adequate Informed Consent
Prior to any medical procedure, an individual is required to be given informed consent.
This is no different in the case of an ill individual seeking to gain early access to an
investigational drug. Before a drug company will allow an individual to receive a drug through a
compassionate use policy, it will first need to provide that individual with informed consent.48
Informed consent requires that the individual understand the risks of taking the drug, as well as
the potential benefits.49 However, compassionate use by nature involves obtaining a drug before
the manufacturer has had a chance to complete all of its testing for both safety and efficacy.
Thus, the drug manufacturer has only a very limited ability to delineate to an individual all of the
risks that may be involved in taking an experimental drug. Although a drug manufacturer can
inform the patient that there may be a multitude of possible adverse side effects that are yet
unknown, the adequacy of this type of informed consent is questionable. Even more, the
efficacy and thus the benefits that may come from taking the drug are uncertain as well. Thus,
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the informed consent document may be very limited in the amount of information it can convey
to the individual.
This lack of a thorough and comprehensive informed consent process can set the stage for
significant litigation against the drug manufacturer, if the individual were to fall even more ill
after taking the drug. Drug companies may be unwilling to subject themselves to this type of
liability – providing an already very ill patient with a drug that may or may not be effective, and
may indeed cause further harm to the patient. The limited informed consent document and
process may do very little to mitigate any litigation that may ensue from an adverse event.
Numerous legal claims have been raised against researchers and drug companies who
have caused injury to participants during clinical trials. Many of these claims are started based
upon inadequate informed consent processes.
For example, in Gelsinger v University of Pennsylvania, the parents of now deceased
Jesse Gelsinger, who died during a phase I clinical trial, sued the drug company claiming that the
informed consent process failed to disclose that previous subjects in the protocol had died.50 It is
no stretch to say that in cases of compassionate use, an individual harmed may have a similar
claim if the drug companies fail to disclose any adverse events, even an event that had occurred
as early as in the animal and in vitro studies. Even if a drug seems to be safe after it has
completed phase I testing and entered into phase II testing, it is doubtful that there have been no
negative side effects from it. Drug companies may attempt to disclose these events to the
individual, but the possibility of neglecting to mention a tangential adverse event and this leading
to significant liability may cause hesitance for the drug company to want to make its drug
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available for compassionate use. Granted, failure to disclose deaths, as in the Gelsinger case, is
an extreme failure to disclose, it does open the door for one to wonder exactly where the line
would be drawn in relation to information that needs to be disclosed.
The Gelsinger’s also made a products liability and fraud claim against the drug
company.51 Again, drug companies who have not finished all stages of testing may be concerned
that, if harm should ensue after allowing their drug to be used for a compassionate use, they may
face a products liability claim, too.
Furthermore, the fraud claim in the Gelsinger case claimed that the principal investigator
had financial ties to the sponsoring company.52 This was not disclosed during the informed
consent process, and thus the Gelsinger’s claimed that fraud had occurred.53 Yet again, drug
companies may be concerned that if they do not disclose every single financial incentive they
have, they too may be susceptible to a fraud claim. For drug companies who have received a
request for compassionate use, millions of dollars are oftentimes invested into their research.
They have a financial stake in seeing their drug succeed, and at times the researcher does as well.
If all of this is not disclosed to the individual seeking compassionate use, the drug companies
may set themselves up to be vulnerable to a fraud claim. Even for a drug company that is “on
the up and up” and wants to do things properly, the fear of forgetting or failing to disclose some
tangential, possibly relevant information may make them quite hesitant to set themselves up for
the liability that may ensue, all simply for compassionate use, not even to further their own
research.
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Ultimately, drug companies are well aware that they themselves are balancing risks
versus benefits when they run clinical trials. Many of the above mentioned risks also apply to
clinical trials. However, in clinical trials the benefits are huge – that they may be able to
successfully put a drug on market that can treat a serious illness. The risks, though, are huge as
well – harm may come to the research participants, and significant liability may ensue – even if
the company did do all in its power to try to ensure an adequate informed consent process. As
rational actors, many drug companies weigh the benefits versus risks and continue on with their
clinical trials.
However, for compassionate use situations, the benefits to the drug company are
markedly small. The individuals seeking compassionate use are generally not going to be
participants contributing to the research. However, the risks are high for the drug company. An
adverse event may lead to substantial liability, under a whole host of possible claims. Many drug
companies are thus, understandably, reluctant to allow their drugs to be used for compassionate
use.
Significant Harm to the Research Process
Not only can adverse events that occur from compassionate use lead to financial liability
for the drug company, but it can also stymie the research process. Any adverse events – even
those occurring outside of a clinical trial – need to be reported to the FDA.54 A serious adverse
event has the potential to halt the clinical trials, or slow down the overall process.55 Since many
individuals seeking compassionate use are already very ill as is, the odds that they may
experience an adverse event after taking the drug are substantial. Whether or not the adverse
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event is related to the drug may be hard to determine, and thus even if the adverse event had
nothing to do with the drug, the drug company may be forced to halt its research trials or change
its protocol. Furthermore, an adverse event such as death would need to be reported to all future
research participants in order for informed consent to be adequate; the risk of death (in the eyes
of the participants) may in turn lead to a reduction in the amount of participants who are willing
to partake in the research.
Just as the adverse events that may occur would need to be reported and could reduce the
amount of willing future research participants, so too could the compassionate use allowance
reduce the amount of research participants. If individuals know that they are likely to be granted
the drug through the compassionate use program, they will be much less likely to enroll in
clinical trials. Clinical trials at times run with both placebo and non-placebo groups, so
individuals enrolled in the trial are not necessarily guaranteed to be given the potentially
beneficial drug.56 Why enroll in a research study with a 50/50 chance of gaining the drug, when
you can just apply for compassionate use and guarantee yourself the drug? Furthermore, many
research trials can be inconvenient for ill patients. Some trials require significant travel to other
locations or other inconvenience.57 Again, why be burdened with all of that, when you can just
get the drug dispensed to you directly through your treating physician? Thus, drug companies
are hesitant to allow many compassionate use exceptions for their drugs, since this can severely
limit the amount of research participants willing to partake in the clinical trials. Without enough
participants for clinical trials, the research process cannot be adequately completed, and this can
lead to significant delays in getting the drug to market. This hurts not only the drug companies
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who are seeking to make a profit, but society as a whole, which may be eagerly awaiting a new
life saving drug.
Clearly, drug companies lack many incentives to allow their drugs to be used for
compassionate use. As such, individuals have sought to change the procedure for compassionate
use, in order to help motivate drug companies to allow a higher number of sick individuals to
obtain these drugs as soon as possible, as opposed to being forced to die waiting for the years it
may take a drug to gain market approval. Although the desired drug may or may not be
effective, for many people it is the last hope, and the last thing try, when all other forms of
treatment have been exhausted and proven uneffective.
Judicial Avenue
The courts are one avenue which interested parties have utilized to attempt to make it
easier to obtain drugs through compassionate use. Rather than worry about creating incentives
for drug companies to expand their cases of compassionate use, these individuals have first
focused on attempting to change certain FDA regulations that restrict compassionate use cases.
The most stringent statutory provision, and the one litigated, has been the provision that prohibits
the sale of post-phase I drugs, drugs which have not gotten too far in the clinical testing process.
Abigail Alliance generated a great deal of notoriety when it filed suit against the FDA,
attempting to enjoin it from enforcing its policy restricting compassionate uses of drugs which
have just completed phase I testing.58 Alliance argued that this restriction was an infringement
upon due process rights.59
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Initially, their claim was dismissed, with the lower court finding that there was no
fundamental right to use investigational new drugs to save or extend one’s life.60 Two years
later, the United States Court of Appeals for the District of Columbia reversed this decision,
holding that competent, terminal patients with no other alternatives do indeed have a
fundamental right to use investigational drugs to save or extend their lives.61
Finally, in August of 2007, the District of Columbia Circuit Court used rational basis
review to determine that the government had a legitimate interest in ensuring that individuals
were not subjected to unreasonable risks from investigational new drugs.62 Thus, FDA’s policy
limiting access to investigational drugs as early as post phase I was indeed constitutional.63
The judicial route, even if it had been successful, would be unlikely to ameliorate the
current issues – many terminal patients are not able to obtain potentially life-saving drugs when
they need them. The FDA itself generally approves compassionate use requests. It is often times
the drug companies themselves who decline the requests. Thus, even if the judiciary were to
require the FDA to change its regulations and allow compassionate use requests for drugs postphase I, this would not mean the individuals would necessarily be able to obtain these drugs that
early in the clinical testing process. Drug companies would be even more unlikely to approve
compassionate use requests so early in the testing process, when the possibility for adverse
events and ensuing liability is even greater.
Thus, it does not seem that the judicial avenue is the best way to help remedy the current
situation. The other avenues in which individuals have tried to affect change have been more
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fruitful for, at the very least, they have generated many potential solutions to be placed on the
table.
Legislative Proposal
One legislative proposal that gained a great deal of attention is Senator Brownback’s
2008 ACCESS Act proposal. Although it ultimately did not pass, the bill advocated several
ideas intended to increase the availability of investigational drugs to terminal patients more
quickly than the current process.64
For one, the bill built upon Alliance’s attempt to allow terminal patients to access drugs
as early as post Phase I. The bill set up provisions under which an investigational drug can
essentially gain market approval after Phase I testing, provided that the drug company can
present sufficient evidence to the FDA that the safety and efficacy of the drug will provide more
benefit to the patient than the risk of morbidity or death from the condition or disease.65 This
threshold is actually relatively low, for even if there is some risk to a drug, the terminal patient is
already facing death as a very real possibility. Thus, if the FDA were to perform a balancing
assessment using that standard, it seems that they would almost always weigh in favor of
approval of the post Phase I drug.
Yet, the great majority of drugs that pass Phase I testing end up failing for either safety or
efficacy reasons.66 Thus, one has to consider the implications of allowing terminal patients
broad access to these drugs at such an early stage. Terminal patients might end up forgoing other
conventional, more promising methods of treatment in lieu of trying a new drug, which is very
64
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likely to end up proving ineffective. Additionally, the new drug may have adverse side effects
that have not yet been discovered so early in the testing process. As a result, a terminal patient
may end up choosing to forgo dying in a comfortable and dignified matter, and instead be
subjected to numerous unnecessary discomforts and grievances at the end of his life.
While it is true that many drugs that pass Phase I testing do indeed provide a cure or at
least mitigate a serious disease or condition, the fact that so many drugs do end up failing
provides a strong case for not allowing patients access to drugs this early in the testing process.
Even for drugs that do offer a cure or mitigate a disease or condition, there are side effects that
may not be known so early in the testing process; some of these effects might so severe that they
do not outweigh the possibility of morbidity or death. For example, a severe stroke which leaves
a person permanently and severely disabled may be worse than death, for some individuals. It is
difficult for the FDA to truly weigh the risks and benefits of a drug as early as post Phase I, for
many of the risks may not yet become known. Thus, although this part of the ACCESS Act’s
proposal is well intended, it seems that it could end up doing more harm than good to terminal
patients.
The bill attempts to provide some safeguards rather than just broadly granting access for
patients to approved post Phase I drugs.67 The first safeguard is the requirement that a patient
who wishes to obtain the drug must provide written informed consent.68 As discussed earlier in
this paper, attempting to provide informed consent before many of the risks are known causes
one to question just how adequate this informed consent could be.
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The second safeguard requires that a patient provide a written waiver of the right to sue
the manufacturer (along with the sponsor, physician, or any institution) for any adverse events
that may occur.69 One possible issue with this provision is that a terminal patient, fearing death
and feeling hopeless, may not even competent to sign a waiver, thereby voiding the entire
waiver. While this may or may not be true, it is definitely a claim a lawyer may bring in
attempting to hold a drug company liable. Lawsuits could end up bankrupting a company or
limiting the funds available to finish the research process’ phase II and phase III testing.
The final safeguard for a patient wishing to obtain these drugs is that the patient must
provide consent that the sponsor can obtain information on the drug’s usage in the patient.70
This provision is rational and initially seems helpful. The drug manufacturer will be able to
obtain even more data. But, what if this data is negative? Many of the patients seeking these
drugs may be close to death to begin with. If a death occurs while taking the drug, this may need
to be reported as an adverse event. Too many deaths or adverse events may lead the FDA to
compel the drug manufacturer to stop clinical trials with the drug, and thus may prevent a helpful
drug from getting to market. One could argue that it is better to allow the drug to be tested in
controlled, clinical trials, to ensure that any adverse events are a result of the drug, and thereby to
allow the FDA to make a more valid assessment of the drug’s safety and efficacy. Allowing
individuals outside a controlled trial to easily gain access to these drugs may increase the amount
of adverse events reported – which may or may not be tied to the drug. This could stymie the
research process and ultimately prevent a good drug from getting to market. While it is possible
that the drug may help terminal patients improve or even recover, thus creating a positive event
which would be beneficial to the research process, the fact that patients requesting
69
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compassionate use are knocking at death’s door already makes it more likely that adverse events
will be more frequent.
Thus, the portion of the ACCESS Act that attempts to allow post Phase I drugs to get to
market is misguided, and the safeguards do little to make this allowance any better. Patients may
end up worse off, and the public as a whole may end up worse off as well, for this type of access
may ultimately impede the clinical research process and the ability of drugs to make it through
all stages of the clinical trial process and reach the public as a whole.
Additionally, the ACCESS Act proposes a prohibition on placebo groups in clinical trials
with “respect to any life-threatening condition or disease where reasonably effective approved
alternative therapies exist for the specified indication.”71 This regulation presumably would
prevent terminal individuals from being forced to make a choice between a known method of
treatment, such as radiation for cancer, and participation in a study with a promising new drug,
yet only a 50-50 chance of actually being given this drug. While this regulation is intended again
to increase a chance of a patient gaining access to a promising new drug, it could ultimately hurt
the research process, as clinical trials are at times more thorough when they have both a placebo
and non-placebo group. Furthermore, there is no guarantee that the drugs in these trials will
actually be effective in treating the specific disease or condition they are targeted against. Thus,
an individual who forgoes a proven method of treatment, such as radiation, is essentially taking a
gamble by participating in a clinical trial – even if they were to know they would be given the
new drug. Since these individuals are taking a gamble by participating in a clinical trial
regardless, and placebo groups are essential to thorough research, the provision to eliminate
placebo groups is also a misguided attempt at remedying the limited access ill patients have at
71
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obtaining investigational, promising new drugs.
The most positive and potentially beneficial proposal under the ACCESS Act is that of
the creation of an Accelerated Approval Advisory Committee.72 This committee would be made
up of independent professionals whose job would entail reviewing applications and issuing
recommendations to the Secretary of Health and Human Services.73 This committee would serve
to expedite the approval process.74 Expediting the approval process seems a great starting point
for helping terminal patients obtain drugs more quickly.
2009 Regulatory Changes
The FDA reacted to the ACCESS Act and public pushback by revising its regulations in
2009.75 These regulations allows for expand compassionate use situations in both individuals as
well as intermediate size populations that are eligible.76 The criteria for granting access require
that “the drug is intended to treat a ‘serious or immediately life-threatening disease or condition’
for which there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat
the disease or conditions; that the potential patient benefit outweighs the potential risks; and that
providing the drug for treatment uses will not interfere with the clinical investigations that could
support marketing approval.”77
This rule seems to help mitigate some of the concerns with compassionate use. For one,
it ensures that patients are not forgoing a more reliable cure in favor of the new, investigational
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drug. The regulation specifically requires that there be no comparable or satisfactory
alternative.78
Furthermore, the regulation helps protect the integrity of the clinical trials process, by
requiring, too, that the compassionate use will not interfere with clinical investigations.79 While
this theoretically may be hard to ensure – compassionate use exceptions may undoubtedly limit
the amount of participants willing to participate in clinical trials when they can attempt to just
obtain the drug directly – the regulation at least gives drug companies something to fall back on
if they wish to deny a compassionate use request. In essence, drug companies will have a firm
footing to deny compassionate use requests if need be. Rather than look like “the bad guy” for
denying someone’s request, a drug company has a legitimate argument that the request must be
denied if it will interfere with its research process.
In sum, these current regulations are the best possible outcome in terms of the delicate
balancing act between allowing for compassionate use, and recognizing that there are a great
deal of reasons not to allow for compassionate use. These regulations, with their stringent
criteria for allowing for compassionate use, grant a great deal of latitude to drug companies.
While a drug company would never be required to grant someone compassionate use, these
regulations give drug companies several valid ways in which they can deny compassionate use
requests without seeming to do so for no good reason. Denying compassionate use requests is
oftentimes necessary in order to adequately complete the research process, and thus these
regulations ensure that drug companies are able to do so more easily.
The Best Balance
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What, then, is the best balance between the competing interests of terminal patients, who
have an urgent need to obtain a potentially life-saving drug as quickly as possible, and drug
companies, which have a plethora of valid reasons not to give drugs to patients too early in the
clinical trials process?
First, the compassionate use procedure as it exists now is the best balance of these
interests. The FDA has implemented strict oversight to insure that compassionate use exceptions
are allowed for the individuals who need them. The burden falls on the drug companies to
decide when to allow their drug to be given outside the clinical testing process. While some
have continued to argue that the regulations should be less strict, this paper has shown that there
are valid reasons to keep the regulations as they stand now.
However, keeping the policy as it stands will still allow for compassionate use exceptions
in many cases. In 2013, for example, the FDA approved a total of 974 compassionate use
cases.80 Rather than attempt to make the regulations more relaxed, individuals have garnered
success by turning to social media, in order to put pressure on drug companies to approve
compassionate use requests.
For example, Merck expanded access to its investigational drug shortly after Nick Auden
passed away in November 2013.81 Merck spokesman Ian McConnell stated, “We have been
accelerating all aspects of the development program to bring this investigational medicine to as
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many people who might benefit from it as quickly and fairly as possible.”82 While the drug
company has financial motives in moving along its clinical trials process as efficiently as
possible, one could argue that the media pressure from Nick Auden’s situation increased their
desire to get the drug to a point in which they felt confident that it would be safe and effective for
compassionate use cases. McConnell stated, “Now that we have more safety and efficacy data in
melanoma, and we have adequate supply we have started our planned [Expanded Access
Program] in the U.S. for treatment of eligible patients with advanced melanoma.”83 One could
argue that societal pressure and the desire to maintain a positive reputation motivated Merck to
work efficiently to get its drug to that point quickly. The pressure from the media helps keep a
drug company balanced in that it has more motivation to approve compassionate use cases when
it feels it can safely do so. A drug company that does not allow for any compassionate use with
its drug may garner a negative public image that it does not want. However, a drug company
that just blindly allows a drug to be used for compassionate use too early in the drug trials
process may also garner significant negative attention if there are severe adverse side effects –
such as death – from its drug. Thus, the current FDA regulations balanced with the role of
societal pressure, particularly in the role of social media, help keep a healthy balance between
approval and rejection of compassionate use requests.
This was also evidenced in the recent case of Josh Hardy, a 7 year old boy, who after
fighting cancer for most of his life, was on death’s door as he fought against an adenovirus.84
Josh’s family made a compassionate use request for the drug brincidofivir and was initially
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denied.85 The drug had shown great promise in clinical research up to that point, and even Josh’s
doctors at St. Jude Children’s Research Hospital put pressure upon the drug company to allow
for this compassionate use.86 The drug company’s denial seemed to have little to do with safety,
and more to do with a limited supply.87 The company argued that if it opened the door for Josh it
would open the door for several others who had requested compassionate use – in the past two
years, over 80 people have requested a compassionate use for the drug.88 In the clinical trials
process supplies are limited, and drug companies do not have endless funds to invest in making
more drugs which are not to be used in the research process.89 This rationale did not deter Josh’s
family, who set up a Facebook page and went to the media – garnering nationwide sympathy and
attention to the case.90 The overwhelming public pressure resulted in the drug company
changing its stance and allowing for compassionate use both for Josh, and several other
individuals who had requested the drug.91 Thus, again, social media put pressure on the drug
company to do the right thing given the circumstances.
There is no need to change regulations or the legal framework for compassionate use – as
it stands, there is sufficient latitude for drug companies to allow for compassionate use in
situations in which it is appropriate. While some may argue that there is little incentive for the
drug companies to do so, it is evident that the desire to maintain a positive image and the power
of social media are motivation enough.
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Furthermore, allowing for more promising drugs to get to market more quickly and
efficiency will help improve outcomes for both terminal patients and drug companies. The FDA
Safety and Innovation Act of 2012 aims to do this, both by creating a new “breakthrough
therapy” designation for promising investigational drugs, and by expanding situations in which
accelerated approval can occur.92
The breakthrough category is for drugs which are intended to treat a “serious or lifethreatening disease or condition” and which have shown through early studies that they may
demonstrate a substantial improvement over current therapies.93 Drugs that fall into this
category get on track to get approved more quickly, for the FDA commits to working closely
with the drug company to ensure efficient tests for safety and efficacy, with goals to get the drug
to market more quickly.94
Ideally, all drugs that show significant promise will be able to be approved as either a
breakthrough therapy or as qualified for accelerated approval. Going forward, the FDA should
expand its resources to increase its staff and ensure that there are ample individuals to work one
on one with each and every drug company that submits an INDA for a drug that has the potential
to show significant promise in treating a serious disease or condition.
Approving a drug more quickly benefits both the patients and the drug companies.
Patients will be able to obtain the drug more quickly with more guarantee of safety and efficacy
than they may have if the drug were obtained through a compassionate use program. Drug
companies will be able to give their drug to individuals and have a higher degree of confidence
in its safety and efficacy; additionally, by getting the drug approved more quickly and efficiently,
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they will be able to market the drug and make a profit from all the money and time that were
invested in their research. Profit is a necessary incentive for drug companies to attempt to create
new drugs, and thus the ability to get their products to market quickly and efficiently will help
incentivize drug innovation, which will result in even more promising treatment options for ill
patients. It is a win-win situation.
Conclusion
While terminal patients’ interests and drug companies’ interests seem inherently
different, they both have the same end desire – to end up with a drug that is safe and effective for
use. Terminal patients want to obtain a potentially beneficial drug as quickly as possible, but
drug companies have to weigh other concerns, such as liability issues that could arise from
allowing for individuals to use the drug too early in the research process, as well as the effect
that compassionate use exceptions could have on the research process.
The best balance to these competing concerns is, first and foremost, to continue to allow
the compassionate use exception to stand as it stands now. The current regulations provide an
appropriate balance between the competing interests of terminal patients and drug companies.
While some may argue that drug companies lack any real motivation to provide drugs in
compassionate use cases, recent situations in the media have shown that this is not true. The
desire for a positive reputation and the power of social media will continue to help keep drug
companies in check and motivated to allow for compassionate use when appropriate.
More promising are the increased opportunities for drug companies to get their drugs to
market more quickly, be it through being designated as a breakthrough therapy or qualifying for
some type of accelerated approval. Ideally, the FDA will invest heavily in more resources and

man power, so they can work closely with any and all drug companies which submit an INDA
for a promising new drug. This will help shorten the normally cumbersome and lengthy drug
review process and ideally lead to drugs getting to market much more quickly, but still showing
the same promise of safety and efficacy that is normally established over an average seven year
period. Thus, drug companies get their drugs to market more quickly and terminal patients
receive a promising new treatment more quickly and with more assurance of both safety and
efficacy.

